c-Src and Pyk2 protein tyrosine kinases play protective roles in early HIV-1 infection of CD4+ T-cell lines

J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):118-26. doi: 10.1097/QAI.0000000000000105.

Abstract

Background: During early HIV-1 infection of CD4 T-lymphocytes, many host protein tyrosine kinases become activated within minutes, including phosphoprotein pp60 (c-Src) and the focal adhesion kinase family member, proline-rich tyrosine kinase 2 (Pyk2). Whether their activation facilitates or impedes infection remains to be determined.

Methods: c-Src kinase inhibitors (SU6656, PP1, and PP2), adenovectors [wild-type and dominant-negative (DN) c-src] or siRNA (targeting c-src or pyk2) were used to inhibit, compete with or knockdown c-Src in Jurkat C, Jurkat E6-1, Hut 78 or Kit225 T-cell lines. Cells were then infected with HIV-1 luciferase reporter virus expressing VSV-G or HXB2(X4) envelope, and luciferase activity was measured after 2 days. Reverse transcriptase activity and viral cDNA were measured 1 hour after infection, whereas integrated virus was measured 12 hours after infection.

Results: Pretreating Jurkat T-cells with SU6656 led to increased VSV-G luciferase activity. In the adenovector experiments, T-cells overexpressing dominant-negative c-Src, but not wild-type c-Src, showed increased luciferase activity after VSV-G infection. siRNA knockdown of c-Src or Pyk2, followed by HXB2 infection in Jurkat T-cells, lead to increased reverse transcriptase activity, viral cDNA, integrated virus, and increased luciferase activity.

Conclusions: Pyk2 is known to interact with c-Src. Thus, Pyk2 activation that coincides with increased c-Src activity during HIV-1 infection could be responsible for c-Src activation. Reduced c-Src activation increases HIV-1 reverse transcription, integration, and/or transcription, suggesting the high c-Src activity seen early in HIV-1 infection may be a cellular response to slow or prevent early infection in CD4 T-cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD4-Positive T-Lymphocytes / virology*
  • CSK Tyrosine-Protein Kinase
  • Cell Line, Tumor
  • DNA, Viral / isolation & purification
  • Focal Adhesion Kinase 2 / antagonists & inhibitors
  • Focal Adhesion Kinase 2 / genetics
  • Focal Adhesion Kinase 2 / metabolism*
  • HIV Infections / metabolism*
  • HIV-1 / physiology
  • Humans
  • Indoles / pharmacology
  • Membrane Glycoproteins / metabolism
  • Phosphorylation
  • Pyrazoles / pharmacology
  • Pyrimidines / pharmacology
  • Sulfonamides / pharmacology
  • Transduction, Genetic
  • Viral Envelope Proteins / metabolism
  • src-Family Kinases / antagonists & inhibitors
  • src-Family Kinases / genetics
  • src-Family Kinases / metabolism*

Substances

  • 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine
  • AG 1879
  • DNA, Viral
  • G protein, vesicular stomatitis virus
  • Indoles
  • Membrane Glycoproteins
  • Pyrazoles
  • Pyrimidines
  • SU 6656
  • Sulfonamides
  • Viral Envelope Proteins
  • CSK Tyrosine-Protein Kinase
  • Focal Adhesion Kinase 2
  • PTK2B protein, human
  • src-Family Kinases
  • CSK protein, human